1. Brock N (1979) The special position of ifosfamide in the series of cytostatically active oxazaphosphorines. In: Fox BW (ed) Advances im Medical Oncology, Research and Edu- cation, vol 5, Basis for Cancer Therapy 1. Pergamon Press, Oxford New York
2. Brock N, Stekar J, Pohl J, Niemeyer U, Scheffler G (1979) Acrolein, the causative factor of urotoxic side-effects of cyclophosphamide, ifosfamide, trofosf amide and sufosf amide. Arzneim Forsch 29:659–661
3. Brock N, Stekar J, Pohl J, Scheef W (1979) Antidot gegen urotoxische Wirkungen der Oxazaphosphorin-Derivate Cyclophosphamid, Ifosfamid und Trofosf amid. Naturwissenschaften 66:60–61
4. Burkert H, Schnitker J, Fichtner E (1979) Verhütung der Harnwegstoxizität von Oxazaphosphorinen durch einen “Uroprotektor”. Munch Med Wochenschr 121:760–762
5. Klein HO, Christian E, Coerper C, Klein PJ, Scheef W, Brock N, (1978) Experimental and clinical investigation on the protective effect of 2-mercapto-aethan-sulfon-acid (MAS) on kidneys and urinary bladder during high-dose therapy with ifosfamide (IF) and cyclophos- phamide (CPA). Medical Oncology, Abstr., 4th Annual Meeting Oncology Society, Nice, Dec 2–4, 1978